| Literature DB >> 25330091 |
Sofía Feliziani1, Rasmus L Marvig2, Adela M Luján3, Alejandro J Moyano1, Julio A Di Rienzo4, Helle Krogh Johansen5, Søren Molin2, Andrea M Smania1.
Abstract
The advent of high-throughput sequencing techniques has made it possible to follow the genomic evolution of pathogenic bacteria by comparing longitudinally collected bacteria sampled from human hosts. Such studies in the context of chronic airway infections by Pseudomonas aeruginosa in cystic fibrosis (CF) patients have indicated high bacterial population diversity. Such diversity may be driven by hypermutability resulting from DNA mismatch repair system (MRS) deficiency, a common trait evolved by P. aeruginosa strains in CF infections. No studies to date have utilized whole-genome sequencing to investigate within-host population diversity or long-term evolution of mutators in CF airways. We sequenced the genomes of 13 and 14 isolates of P. aeruginosa mutator populations from an Argentinian and a Danish CF patient, respectively. Our collection of isolates spanned 6 and 20 years of patient infection history, respectively. We sequenced 11 isolates from a single sample from each patient to allow in-depth analysis of population diversity. Each patient was infected by clonal populations of bacteria that were dominated by mutators. The in vivo mutation rate of the populations was ∼100 SNPs/year-∼40-fold higher than rates in normo-mutable populations. Comparison of the genomes of 11 isolates from the same sample showed extensive within-patient genomic diversification; the populations were composed of different sub-lineages that had coexisted for many years since the initial colonization of the patient. Analysis of the mutations identified genes that underwent convergent evolution across lineages and sub-lineages, suggesting that the genes were targeted by mutation to optimize pathogenic fitness. Parallel evolution was observed in reduction of overall catabolic capacity of the populations. These findings are useful for understanding the evolution of pathogen populations and identifying new targets for control of chronic infections.Entities:
Mesh:
Year: 2014 PMID: 25330091 PMCID: PMC4199492 DOI: 10.1371/journal.pgen.1004651
Source DB: PubMed Journal: PLoS Genet ISSN: 1553-7390 Impact factor: 5.917
Figure 1Isolate sampling points and patient life spans.
P. aeruginosa isolates were collected from two CF patients: CFA and CFD. Hollow symbols: single bacterial isolates. Solid circles: cross-sectional populations of 90 bacterial isolates. *: estimated start of chronic infection. Gray bar: patient life span.
Mutations in mutS and mutL genes in P. aeruginosa CFA and CFD isolates.
| Isolate | Mutations in MRS genes | Cluster | MRS alleles | |||||
|
|
| |||||||
| CFA | 2004/01 | A739C (T247P) | A1406G (H469R) | SL1 | ||||
| 2007/01 | A739C (T247P) | A1406G (H469R) | I | SL1 | ||||
| 2010/40 | A739C (T247P) | T2381C (L794P) | T1166C (L389S) | A1406G (H469R) | II | SL2 | ||
| 2010/31 | T478A (W160R) | A739C (T247P) | T1166C (L389S) | A1406G (H469R) | III | SL3 | ||
| 2010/01 | T478A (W160R) | A739C (T247P) | T1166C (L389S) | A1406G (H469R) | III | SL3 | ||
| 2010/78 | T478A (W160R) | A739C (T247P) | T1166C (L389S) | A1406G (H469R) | III | SL3 | ||
| 2010/82 | A739C (T247P) | A1406G (H469R) | IVa | SL1 | ||||
| 2010/43 | A739C (T247P) | A1406G (H469R) | IVa | SL1 | ||||
| 2010/72 | A739C (T247P) | A1406G (H469R) | IVa | SL1 | ||||
| 2010/87 | A739C (T247P) | A1406G (H469R) | IVb | SL1 | ||||
| 2010/32 | A739C (T247P) | A1406G (H469R) | IVb | SL1 | ||||
| 2010/26 | A739C (T247P) | A1406G (H469R) | IVb | SL1 | ||||
| 2010/11 | A739C (T247P) | A1406G (H469R) | IVb | SL1 | ||||
| CFD | 1991/01 | |||||||
| 2011/33 | −CG at 1551 | I | SL1 | |||||
| 2002/01 | −CG at 1551 | II | SL1 | |||||
| 1995/01 | −CG at 1551 | III | SL1 | |||||
|
|
|
|
|
| ||||
|
|
|
|
|
| ||||
|
|
|
|
|
| ||||
|
|
|
|
|
| ||||
|
|
|
|
|
| ||||
| 2011/83 | −CG at 1551 | V | SL1 | |||||
| 2011/27 | −CG at 1551 | V | SL1 | |||||
| 2011/34 | −CG at 1551 | V | SL1 | |||||
| 2011/28 | −CG at 1551 | VI | SL1 | |||||
| 2011/94 | −CG at 1551 | VI | SL1 | |||||
SNP and indel mutations were considered.
Clusters were defined according to maximum-parsimony phylogenetic trees (Figure 2).
Amino acid changes are shown in parentheses. Boldface: CFD isolates with reductions in mutation rate. +: insertion. −: deletion.
Figure 2Evolutionary relationships among isolates from CFA and CFD lineages.
Maximum-parsimony phylogenetic trees of CFA (A) and CFD (B) were constructed based on the accumulation of new SNPs relative to ancestors CFA_2004/01 and CFD_1991/01. Alleles of P. aeruginosa reference strain PAO1 were used to root the trees. Lengths of branches are proportional to the number of accumulated SNPs. Branches are designated by capital letters. MRCA: most recent common ancestor.
Figure 3Minimum spanning trees (MSTs) of genomes among CFA and CFD lineages.
MSTs for CFA (A) and CFD (B) were constructed based on the total number of genes altered by nonsynonymous SNPs and indel mutations in the respective genomes. Links between nodes represents the minimum distance in terms of mutated genes. Numbers above each link indicate the total amount of mutated genes between the two connected nodes (Table S6). For tree construction, ancestors CFA_2004/01 and CFD_1991/01 were considered as origins.
Evidence for parallel evolution. Genes identified as being independently mutated in at least a half of the coexisting CFA I–IV and CFD I–VI sub-lineages.
| Gene ID | Gene name | Function classification | Total number of independent mutations | Number of sub-lineages convergently mutated | |
| CFA | CFD | ||||
| PA3327 | Adaptation, Protection | 5 | 2 | 3 | |
| PA4110 |
| 6 | 1 | 5 | |
| PA0074 |
| Adaptation, Protection; Translation, post-translational modification, degradation; Protein secretion/export apparatus | 5 | 2 | 3 |
| PA5015 |
| Amino acid biosynthesis and metabolism; Energy metabolism | 5 | 2 | 3 |
| PA5418 |
| Carbon compound catabolism | 5 | 1 | 4 |
| PA4418 |
| Cell division; Cell wall/LPS/capsule | 6 | 1 | 5 |
| PA2231 |
| Cell wall/LPS/capsule | 5 | 1 | 4 |
| PA2238 |
| 5 | 1 | 4 | |
| PA5213 |
| Central intermediary metabolism; Amino acid biosynthesis and metabolism | 5 | 1 | 4 |
| PA4285 |
| DNA replication, recombination, modification and repair | 5 | 2 | 3 |
| PA0794 | Energy metabolism | 5 | 2 | 3 | |
| PA1613 | Membrane proteins | 6 | 4 | 2 | |
| PA2072 | 5 | 3 | 2 | ||
| PA3234 | Membrane proteins; Transport of small molecules | 5 | 2 | 3 | |
| PA3920 | 5 | 1 | 4 | ||
| PA4719 | 5 | 3 | 2 | ||
| PA0994 |
| Motility & Attachment | 6 | 3 | 3 |
| PA1099 |
| Motility & Attachment; Transcriptional regulators; Two-component regulatory systems | 5 | 1 | 4 |
| PA1523 |
| Nucleotide biosynthesis and metabolism | 5 | 2 | 3 |
| PA3763 |
| 7 | 4 | 3 | |
| PA3895 | Transcriptional regulators | 5 | 2 | 3 | |
| PA4937 |
| Transcription, RNA processing and degradation | 5 | 2 | 3 |
| PA4266 |
| Translation, post-translational modification, degradation | 9 | 4 | 5 |
| PA2018 |
| Transport of small molecules; Membrane proteins; Antibiotic resistance and susceptibility | 7 | 3 | 4 |
| PA0928 |
| Two-component regulatory systems | 6 | 1 | 5 |
| PA1336 | 5 | 2 | 3 | ||
| PA3271 | 6 | 0 | 6 | ||
| PA2378 | Putative enzymes | 6 | 2 | 4 | |
| PA4513 | 6 | 1 | 5 | ||
| PA4489 |
| Hypothetical, unclassified, unknown; Adaptation, protection | 6 | 2 | 4 |
| PA1874 | Hypothetical, unclassified, unknown; Antibiotic resistance and susceptibility | 8 | 3 | 5 | |
| PA1669 | Hypothetical, unclassified, unknown; Membrane proteins | 5 | 1 | 4 | |
| PA0454 | Hypothetical, unclassified, unknown | 6 | 2 | 4 | |
| PA0788 | 5 | 0 | 5 | ||
| PA2077 | 5 | 1 | 4 | ||
| PA2151 | 5 | 2 | 3 | ||
| PA2635 | 5 | 1 | 4 | ||
| PA3728 | 5 | 2 | 3 | ||
| PA4735 | 5 | 3 | 2 | ||
| PA4836 | 5 | 1 | 4 | ||
The categories used for functional classification were as described in the The Pseudomonas aeruginosa Community Annotation Project (http://www.pseudomonas.com).
Figure 4Pathoadaptive genes convergently mutated in CFA and CFD sub-lineages.
The analysis was performed based only on non-synonymous mutated genes that were altered independently in at least half of the 10 evolving sub-lineages CFA I–IV and CFD I–VI.
Figure 5Mutational spectra and top mutated homopolymeric G∶C SSRs in CFA_2010 and CFD_2011 contemporary isolates.
(A) Percentage of 1–4 bp insertions/deletions located in G∶C and A∶T homopolymeric sequences. (B) The heat map represents individual indels mutations in homopolymeric G∶C SSRs of ≥6 bp, which were mutated in at least half of the coexisting isolates in both CFA and CFD lineages. The color-code indicates the type of mutation. Right: Percentage of MRS-deficient isolates harboring a indel mutation in each analyzed G∶C SSR. (C) Mutations in CFA_2010 and CFD_2011 isolates were analyzed based on the percentage of transitions, transversions, and insertions/deletions.
Figure 6Average total catabolic function of isolates from CFA and CFD lineages.
Total catabolic function was calculated relative to CFA_2004/01 and CFD_1991/01 as a weighted average across all substrates for each CFA (A) and CFD (B) isolate. Total catabolic function was defined as 1 for the reference levels (CFA_2004/01 and CFD_1991/01). Lower values indicate decay. Isolates CFA_2010/01, CFA_2010/11, and CFA_2010/31 were excluded from the analysis because significant dispersion was observed in the duplicates.